# A Study of TRK-950 in Patients With Advanced Solid Tumors

> **NCT05423262** · PHASE1,PHASE2 · RECRUITING · sponsor: **Toray Industries, Inc** · enrollment: 49 (estimated)

## Conditions studied

- Solid Tumor
- Melanoma

## Interventions

- **BIOLOGICAL:** TRK-950
- **BIOLOGICAL:** TRK-950
- **BIOLOGICAL:** TRK-950
- **DRUG:** Nivolumab
- **BIOLOGICAL:** TRK-950

## Key facts

- **NCT ID:** NCT05423262
- **Lead sponsor:** Toray Industries, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-06
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 49 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05423262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05423262, "A Study of TRK-950 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05423262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*